{"id":"lenalidomide-bortezomib","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Peripheral neuropathy"},{"rate":"25-40","effect":"Thrombocytopenia"},{"rate":"20-35","effect":"Anemia"},{"rate":"15-30","effect":"Neutropenia"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"20-30","effect":"Fatigue"},{"rate":"5-15","effect":"Venous thromboembolism"}]},"_chembl":{"chemblId":"CHEMBL325041","moleculeType":"Small molecule","molecularWeight":"384.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bortezomib is a proteasome inhibitor that blocks protein degradation pathways, leading to accumulation of pro-apoptotic proteins and tumor cell death. Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activity while also providing direct anti-angiogenic and anti-proliferative effects. Together, they provide synergistic anti-myeloma activity through complementary mechanisms.","oneSentence":"Lenalidomide and bortezomib work together to inhibit proteasome function and enhance immune-mediated tumor cell death, commonly used in multiple myeloma treatment.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:29.884Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed and relapsed/refractory)"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT06152575","phase":"PHASE3","title":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-08","conditions":"Multiple Myeloma","enrollment":492},{"nctId":"NCT03173092","phase":"PHASE4","title":"A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2017-11-13","conditions":"Multiple Myeloma","enrollment":141},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT04133636","phase":"PHASE2","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-07","conditions":"Multiple Myeloma","enrollment":210},{"nctId":"NCT06353022","phase":"PHASE2","title":"Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-06-26","conditions":"Multiple Myeloma","enrollment":103},{"nctId":"NCT04181827","phase":"PHASE3","title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-12","conditions":"Multiple Myeloma","enrollment":419},{"nctId":"NCT04722146","phase":"PHASE1","title":"A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-12","conditions":"Multiple Myeloma","enrollment":140},{"nctId":"NCT06208150","phase":"PHASE3","title":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-01-22","conditions":"Multiple Myeloma","enrollment":795},{"nctId":"NCT06577025","phase":"PHASE2","title":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-08-20","conditions":"Multiple Myeloma","enrollment":43},{"nctId":"NCT07149857","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-10-03","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT04923893","phase":"PHASE3","title":"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-19","conditions":"Multiple Myeloma","enrollment":743},{"nctId":"NCT06142396","phase":"EARLY_PHASE1","title":"Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure","status":"RECRUITING","sponsor":"Augusta University","startDate":"2024-11-01","conditions":"Multiple Myeloma, Renal Failure","enrollment":30},{"nctId":"NCT04151667","phase":"PHASE2","title":"Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-22","conditions":"Multiple Myeloma","enrollment":33},{"nctId":"NCT03984097","phase":"PHASE1","title":"A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2019-07-29","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT04802356","phase":"PHASE2","title":"Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2021-04-07","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT04656951","phase":"PHASE2","title":"Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cologne","startDate":"2021-06-01","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT03729804","phase":"PHASE3","title":"Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-07","conditions":"Multiple Myeloma","enrollment":250},{"nctId":"NCT01919086","phase":"PHASE2","title":"Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-08-06","conditions":"Multiple Myeloma (MM)","enrollment":30},{"nctId":"NCT05870917","phase":"PHASE2","title":"A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-04-25","conditions":"Plasma Cell Leukemia","enrollment":20},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma","enrollment":1450},{"nctId":"NCT00378105","phase":"PHASE1, PHASE2","title":"Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2006-09","conditions":"Multiple Myeloma","enrollment":68},{"nctId":"NCT07428369","phase":"PHASE2, PHASE3","title":"A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-06-05","conditions":"Multiple Myeloma (MM)","enrollment":1570},{"nctId":"NCT05804032","phase":"PHASE3","title":"Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"University of Heidelberg Medical Center","startDate":"2023-04-14","conditions":"Multiple Myeloma","enrollment":514},{"nctId":"NCT06348147","phase":"PHASE2","title":"Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation","status":"SUSPENDED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-07","conditions":"Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation","enrollment":39},{"nctId":"NCT05572515","phase":"PHASE3","title":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-29","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":614},{"nctId":"NCT03710603","phase":"PHASE3","title":"Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2018-12-14","conditions":"Multiple Myeloma","enrollment":709},{"nctId":"NCT04751877","phase":"PHASE3","title":"Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2021-07-17","conditions":"Multiple Myeloma, Myeloma","enrollment":270},{"nctId":"NCT03617731","phase":"PHASE3","title":"Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2018-10-18","conditions":"Multiple Myeloma","enrollment":662},{"nctId":"NCT07297329","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-12-29","conditions":"Multiple Myeloma (MM)","enrollment":292},{"nctId":"NCT05556616","phase":"PHASE1","title":"A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-01-12","conditions":"Multiple Myeloma","enrollment":15},{"nctId":"NCT05137054","phase":"PHASE1","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-17","conditions":"Multiple Myeloma","enrollment":317},{"nctId":"NCT01208662","phase":"PHASE3","title":"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paul Richardson, MD","startDate":"2010-09","conditions":"Multiple Myeloma","enrollment":729},{"nctId":"NCT03652064","phase":"PHASE3","title":"A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-06","conditions":"Multiple Myeloma","enrollment":395},{"nctId":"NCT02312102","phase":"PHASE1","title":"Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-02","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":22},{"nctId":"NCT07341867","phase":"PHASE1","title":"Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype","status":"NOT_YET_RECRUITING","sponsor":"Andrew Hantel, MD","startDate":"2026-06","conditions":"Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation","enrollment":90},{"nctId":"NCT02441686","phase":"PHASE2","title":"Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT07334535","phase":"PHASE4","title":"Isa-VRD in TIE HRMM","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-30","conditions":"Multiple Myeloma","enrollment":117},{"nctId":"NCT05231629","phase":"PHASE2","title":"Sequential Therapy in Multiple Myeloma Guided by MRD Assessments","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-12-13","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT01208766","phase":"PHASE3","title":"Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2011-01","conditions":"Multiple Myeloma","enrollment":1503},{"nctId":"NCT05675319","phase":"PHASE3","title":"Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2023-03-03","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT04991103","phase":"PHASE2","title":"Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Multiple Myeloma, Amyloidosis","enrollment":40},{"nctId":"NCT05695508","phase":"PHASE2","title":"GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5","status":"RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2022-12-01","conditions":"Multiple Myeloma","enrollment":160},{"nctId":"NCT04653246","phase":"PHASE2","title":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacob Laubach, MD","startDate":"2021-07-13","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant","enrollment":52},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT04068597","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","status":"RECRUITING","sponsor":"CellCentric Ltd.","startDate":"2019-08-09","conditions":"Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma","enrollment":250},{"nctId":"NCT02461888","phase":"PHASE2","title":"Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":112},{"nctId":"NCT07285239","phase":"PHASE3","title":"Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":500},{"nctId":"NCT03829371","phase":"PHASE4","title":"STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turin, Italy","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT04091126","phase":"PHASE1","title":"Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2019-12-18","conditions":"Multiple Myeloma","enrollment":118},{"nctId":"NCT07247097","phase":"PHASE2","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-04-15","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible","enrollment":160},{"nctId":"NCT07025005","phase":"PHASE4","title":"Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-08-30","conditions":"Peripheral Neuropathy, Multiple Myeloma, Neoplasms","enrollment":44},{"nctId":"NCT05564052","phase":"PHASE2","title":"A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-06","conditions":"Lymphoma, Mantle-Cell","enrollment":36},{"nctId":"NCT07206810","phase":"","title":"A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2018-08-01","conditions":"Myeloma","enrollment":419},{"nctId":"NCT07018050","phase":"PHASE2","title":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09-12","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":160},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT01863550","phase":"PHASE3","title":"Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2013-12-06","conditions":"Plasma Cell Myeloma","enrollment":1087},{"nctId":"NCT06497738","phase":"","title":"A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-05-01","conditions":"Multiple Myeloma","enrollment":112},{"nctId":"NCT05900882","phase":"PHASE2","title":"SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-07-15","conditions":"Multiple Myeloma","enrollment":35},{"nctId":"NCT05850286","phase":"PHASE2","title":"A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-04-21","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT05860036","phase":"PHASE2","title":"A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-04-04","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT05979363","phase":"PHASE2","title":"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-08-14","conditions":"Plasma Cell Leukemia","enrollment":20},{"nctId":"NCT07045909","phase":"PHASE2","title":"Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)","status":"RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2025-06-30","conditions":"De Novo Multiple Myeloma, Anitocabtagene Autoleucel","enrollment":30},{"nctId":"NCT04790474","phase":"PHASE2","title":"Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2021-03-25","conditions":"Multiple Myeloma in Relapse, Refractory Multiple Myeloma","enrollment":61},{"nctId":"NCT06464991","phase":"PHASE3","title":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","status":"RECRUITING","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","startDate":"2024-03-27","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT04052880","phase":"PHASE2","title":"Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Larysa Sanchez","startDate":"2019-10-24","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":17},{"nctId":"NCT06918002","phase":"PHASE3","title":"Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients","status":"RECRUITING","sponsor":"Intergroupe Francophone du Myelome","startDate":"2025-07-09","conditions":"Multiple Myeloma, Newly Diagnosed","enrollment":824},{"nctId":"NCT07051850","phase":"","title":"Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies","status":"RECRUITING","sponsor":"Sung-Soo Park","startDate":"2025-07-14","conditions":"Multiple Myeloma, Relapsed, Multiple Myeloma (MM)","enrollment":174},{"nctId":"NCT05123131","phase":"PHASE2","title":"Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Trials Ireland","startDate":"2022-04-01","conditions":"Multiple Myeloma","enrollment":54},{"nctId":"NCT04775550","phase":"PHASE2","title":"DARA RVD For High Risk SMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Omar Nadeem, MD","startDate":"2021-03-08","conditions":"High-risk Smoldering Multiple Myeloma, Multiple Myeloma","enrollment":61},{"nctId":"NCT06087653","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"Starton Therapeutics, Inc","startDate":"2023-10-02","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT06409702","phase":"PHASE4","title":"Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-06-12","conditions":"Newly Diagnosed, High Risk, MRD","enrollment":59},{"nctId":"NCT01668719","phase":"PHASE1, PHASE2","title":"S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2012-11","conditions":"DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma","enrollment":142},{"nctId":"NCT02719613","phase":"PHASE2","title":"Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2016-07-15","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT05561387","phase":"PHASE3","title":"Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-10-12","conditions":"Plasma Cell Myeloma","enrollment":510},{"nctId":"NCT03412565","phase":"PHASE2","title":"A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-26","conditions":"Multiple Myeloma","enrollment":265},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT06140966","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-10-20","conditions":"Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma","enrollment":54},{"nctId":"NCT01415752","phase":"PHASE2","title":"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2012-08-09","conditions":"Lymphoma, Mantle Cell Lymphoma","enrollment":373},{"nctId":"NCT06913192","phase":"PHASE1","title":"Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Xuzhou Medical University","startDate":"2025-04-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT04939844","phase":"PHASE2","title":"REST - Replacing Steroids in the Transplant Ineligble","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2021-06-29","conditions":"Multiple Myeloma","enrollment":51},{"nctId":"NCT05849610","phase":"PHASE2","title":"Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2023-09-21","conditions":"High-Risk de Novo Multiple Myeloma","enrollment":30},{"nctId":"NCT03544281","phase":"PHASE1, PHASE2","title":"To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-09-20","conditions":"Multiple Myeloma","enrollment":153},{"nctId":"NCT04717700","phase":"PHASE2","title":"Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ida Bruun Kristensen","startDate":"2021-08-18","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT02874742","phase":"PHASE2","title":"Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08-29","conditions":"Multiple Myeloma","enrollment":224},{"nctId":"NCT06796517","phase":"","title":"Immunotherapy in Lymphoma","status":"RECRUITING","sponsor":"Sung-Soo Park","startDate":"2024-06-26","conditions":"Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma Relapsed","enrollment":72},{"nctId":"NCT04786028","phase":"PHASE2","title":"A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Myeloma Research Group","startDate":"2021-12-08","conditions":"Multiple Myeloma","enrollment":72},{"nctId":"NCT05665140","phase":"PHASE2, PHASE3","title":"Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"University Hopsital Schleswig Holstein Campus Lübeck","startDate":"2023-02-03","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":100},{"nctId":"NCT03319667","phase":"PHASE3","title":"A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2017-12-07","conditions":"Plasma Cell Myeloma","enrollment":475},{"nctId":"NCT04140162","phase":"PHASE2","title":"Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-10-05","conditions":"Multiple Myeloma","enrollment":57},{"nctId":"NCT02375555","phase":"PHASE2","title":"Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-05-07","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT01827137","phase":"PHASE1, PHASE2","title":"WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation","status":"COMPLETED","sponsor":"Sellas Life Sciences Group","startDate":"2013-04","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT03000634","phase":"PHASE2","title":"2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2017-04-01","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT05889221","phase":"NA","title":"Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2023-10-23","conditions":"Multiple Myeloma, Myeloma Multiple, Myeloma","enrollment":74},{"nctId":"NCT06505369","phase":"PHASE2","title":"Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients","status":"RECRUITING","sponsor":"North Estonia Medical Centre","startDate":"2024-06-19","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT04352205","phase":"PHASE2","title":"Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure","status":"TERMINATED","sponsor":"Emory University","startDate":"2020-05-07","conditions":"Plasma Cell Myeloma, Renal Failure","enrollment":17},{"nctId":"NCT06463717","phase":"","title":"Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2023-12-01","conditions":"Multiple Myeloma, Minimal Residual Disease","enrollment":210},{"nctId":"NCT05422027","phase":"PHASE1, PHASE2","title":"Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Xia Zhongjun","startDate":"2022-07-25","conditions":"Multiple Myeloma","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":183,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lenalidomide (REVLIMID®)","Bortezomib (VELCADE®)","Bortézomib (VELCADE®)"],"phase":"phase_3","status":"active","brandName":"Lenalidomide, Bortezomib","genericName":"Lenalidomide, Bortezomib","companyName":"University Hospital, Toulouse","companyId":"university-hospital-toulouse","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenalidomide and bortezomib work together to inhibit proteasome function and enhance immune-mediated tumor cell death, commonly used in multiple myeloma treatment. Used for Multiple myeloma (newly diagnosed and relapsed/refractory), Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}